CEO, President & Director of Damora Therapeutics Picks Up 2.5% More Stock

Investors who take an interest in Damora Therapeutics, Inc. (NASDAQ:DMRA) should definitely note that the CEO, President & Director, Jennifer Jarrett, recently paid US$20.23 per share to buy US$253k worth of the stock. Although the purchase only increased their holding by 2.5%, it is still a solid purchase in our view.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Damora Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Jennifer Jarrett was the biggest purchase of Damora Therapeutics shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$20.66 per share to be enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Damora Therapeutics insider decided to buy shares at close to current prices. Jennifer Jarrett was the only individual insider to buy during the last year.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Damora Therapeutics

Damora Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data suggests Damora Therapeutics insiders own 0.2% of the company, worth about US$3.0m. However, it's possible that insiders might have an indirect interest through a more complex structure. We consider this fairly low insider ownership.

So What Does This Data Suggest About Damora Therapeutics Insiders?

It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Damora Therapeutics insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Damora Therapeutics. Every company has risks, and we've spotted 5 warning signs for Damora Therapeutics (of which 3 are a bit concerning!) you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.